StreetInsider.com News Articles

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

Insu Therapeutics Inc., a Vancouver-based biotechnology company in which Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) holds a strategic investment, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its buccal peptide-delivery technology.

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The allowed claims cover the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics. The published application identifies semaglutide, liraglutide, dulaglutide and exenatide, alongside multiple insulin analogues.

The patent allowance supports Insu's two investigational

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

The patent allowance supports Insu's two investigational

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

The patent allowance supports Insu's two investigational

Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery

Thu, 08 Oct 2026 07:30:37 -0400

The patent allowance supports Insu's two investigational

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

VANCOUVER, BC and LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) today announced that Insu Therapeutics Inc. ("Insu"), in which Hydreight holds a strategic investment, has received

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Thu, 08 Oct 2026 07:30:00 -0400

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights

Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A